Drug Policy Watch · State Brief 2026

Georgia

Snapshot (structured)

Adult-use cannabis: Illegal (no legalization bill advancing)
Medical cannabis: Legal, expanded in 2026 (SB 220); NORML now counts Georgia as the 41st medical cannabis state
Home grow: Not permitted (no patient or adult cultivation)
Intoxicating hemp / hemp THC: Legal but newly tightened (SB 33, Act 461, signed May 11 2026, effective Jan 1 2027); 21+ only
Psychedelics: Illegal; no decriminalization or therapeutic-access program enacted
Broad decriminalization: No statewide decrim; several cities have local decriminalization
Harm reduction: Syringe services authorized (2019), naloxone via standing order, drug-checking strips legalized for any substance (2025)
Governor (party): Brian Kemp (Republican), term-limited, leaves office January 2027
Legislature control: Republican trifecta (Senate 33-23 R, House 100-80 R after 2024 elections)
Citizen ballot initiatives allowed: No (Georgia has no statewide initiative or referendum process)
Enclosure pressure score: 4/5

Cannabis

Adult-use cannabis remains illegal in Georgia, and as of the 2026 session there was no recreational legalization bill advancing through the General Assembly. Possession of one ounce or less is a misdemeanor carrying up to one year of imprisonment, and possession of more than one ounce is a felony punishable by one to ten years (https://www.georgiacriminaldefense.com/is-weed-legal-in-georgia-marijuana-laws-less-than-oz-cannabis.html). Several municipalities, including Atlanta, Athens, Savannah, Clarkston, South Fulton, Forest Park, Statesboro, and Stonecrest, have locally reduced penalties; Atlanta caps the penalty for an ounce or less at a $75 fine with no jail (https://norml.org/laws/local-decriminalization/georgia-local-decriminalization/).

Medical cannabis is legal and was significantly expanded in 2026. Georgia first authorized low-THC oil in 2015, but regulators did not license producers until 2023 (https://norml.org/blog/2026/05/13/georgia-expands-patients-access-to-medical-cannabis-products/). On about May 12 2026, Gov. Brian Kemp signed Senate Bill 220, "The Putting Georgia's Patients First Act." SB 220 replaces all statutory references to "low THC oil" with "medical cannabis," removes the prior five percent THC cap, and instead lets patients possess products containing a cumulative total of 12,000 milligrams or less of THC. It permits patients 21 and older to vaporize approved products, adds inflammatory bowel disease and lupus as qualifying conditions, and eases registration requirements for several existing conditions. Patients still may not smoke botanical cannabis, manufacturers may not infuse cannabis into food products, and public use is prohibited (https://norml.org/blog/2026/05/13/georgia-expands-patients-access-to-medical-cannabis-products/, https://www.fox5atlanta.com/news/medical-cannabis-kemp-signs-sb-220-law). The law takes effect July 1 2026, with the Department of Public Health directed to set rules; NORML now classifies Georgia as the 41st medical cannabis state.

Home grow is not permitted, for patients or for adults. There is no provision for personal cultivation in Georgia law.

Market structure is tightly capped and vertically concentrated. The Georgia Access to Medical Cannabis Commission (GMCC) licenses two Class 1 production licenses and four Class 2 production licenses (https://www.gmcc.ga.gov/licensing/class-1-production, https://www.gmcc.ga.gov/licensing/class-2-production). Roughly 15 retail dispensing licenses had been issued, with about six held by Trulieve, and major operators include Trulieve, Botanical Sciences, and Fine Fettle (https://www.cannabisbusinesstimes.com/business-issues-benchmarks/medical-cannabis-access-and-pricing/news/15687742/trulieve-opens-georgias-first-medical-cannabis-dispensaries, https://mjbizdaily.com/georgia-poised-to-add-more-cannabis-permits-under-mmj-expansion/615130/). Over 33,000 patients are enrolled (https://norml.org/blog/2026/05/13/georgia-expands-patients-access-to-medical-cannabis-products/). The exact post-SB 220 license count and any added permits are still being implemented and may be stale; the MJBizDaily report indicates SB 220 is expected to add more retail permits.

Key 2026 action: enactment of SB 220 (medical expansion) and SB 33 (hemp tightening), both signed in May 2026.

Hemp

Intoxicating hemp products, including delta-8, delta-9, delta-10, and THCA items, have been sold legally to adults 21 and older under the Georgia Hemp Farming Act as amended by SB 494 (2024) and the Department of Agriculture's hemp product rules effective October 1 2024 (https://drinksunnydayz.com/blogs/news/are-thc-drinks-legal-in-georgia, https://agr.georgia.gov/hemp-program). The 2024 framework sets a 21+ purchase and possession age, retailer age verification, and serving-size, testing, labeling, and packaging rules for gummies, beverages, tinctures, and topicals.

In 2026 the legislature tightened the regime. Senate Bill 33, amending the Georgia Hemp Farming Act, was signed by Gov. Kemp on May 11 2026 as Act 461, with an effective date of January 1 2027 (https://legiscan.com/GA/bill/SB33/2025, https://trackbill.com/bill/georgia-senate-bill-33-georgia-hemp-farming-act-total-thc-concentration-of-consumable-hemp-products-provide-limits/2633757/, https://www.ajc.com/politics/age-limits-and-testing-requirements-approved-for-georgia-hemp-products/PFFMKFSHR5BOJFTYV67FQMA4X4/). SB 33 provides limits on total THC concentration of consumable hemp products, revises certificate-of-analysis requirements, expands definitions, authorizes impounding of noncompliant products, and sets new penalties; reporting indicates it targets synthetic cannabinoids such as HHC for a 2027 ban while leaving certain delta-8 products on the market, and reflects federal cannabinoid-beverage language. The precise per-serving and per-container milligram caps in the enacted version are not fully reconciled across sources; the 5mg/serving and 150mg/container figures and the 0.4mg-per-container figure appeared in earlier draft discussion and should be treated as unconfirmed for the final enacted text. One letter to Gov. Kemp opposing SB 33 is on file (https://georgiarecorder.com/wp-content/uploads/2026/05/Letter-to-Gov.-Kemp-re-SB-33-May-10-2026-final.pdf). Note: at least one secondary blog claimed no hemp bill passed in 2026; that claim is contradicted by LegiScan, TrackBill, AJC, and the Governor's signing records, which confirm SB 33 became law.

Federal exposure is significant. President Trump signed H.R. 5371 (Continuing Appropriations and Extensions Act of 2026) on November 12 2025, which rewrites the federal hemp definition to a 0.3 percent total-THC standard and caps consumer products at 0.4 milligrams of total THC per container, with delta-8 and delta-10 treated as synthetic and banned. These changes take effect November 12 2026 (https://herb.co/news/farm-bill-loophole, https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains, https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf). Because Georgia has no adult-use cannabis market to absorb displaced products, the bulk of the state's intoxicating-hemp retail market is exposed to elimination on that federal deadline, on top of SB 33's January 1 2027 state changes.

Psychedelics

Psychedelics remain illegal in Georgia, and no decriminalization, therapeutic-access, or research program has been enacted as of 2026. Two relevant 2025-2026 bills were introduced. HB 717 would allow psychedelic-assisted treatment, once FDA approved, delivered by certain licensed clinicians, with a board to write rules and licenses contemplated from July 1 2026 in the bill's text; it did not become law (https://psychedelicalpha.com/news/march-2025s-psychedelic-policy-momentum-new-bills-filed-across-the-u-s-as-nearly-30-states-deliberate-reforms). HB 382 would modify how psilocybin is scheduled, creating an exception for FDA-approved drugs containing crystalline-polymorph psilocybin (https://legiscan.com/GA/bill/HB382/2025, https://www.billtrack50.com/billdetail/1828478). Neither establishes broad decriminalization or a state therapy program.

Broader drug policy

There is no statewide decriminalization of cannabis or other drugs; reductions exist only at the municipal level (Atlanta, Athens, Savannah, and others) (https://norml.org/laws/local-decriminalization/georgia-local-decriminalization/).

Harm reduction is comparatively developed for a Deep South state. Syringe service programs have been legally authorized since 2019-2020 (https://www.networkforphl.org/wp-content/uploads/2024/08/2024-50-State-DCE-Fact-Sheet.pdf). Naloxone is available from pharmacies without an individual prescription under a statewide standing order, and the Department of Public Health's Opioid and Substance Misuse Response Program distributes naloxone and fentanyl test strips, including through repurposed 24-hour supply boxes (https://dph.georgia.gov/stopopioidaddiction/opioid-and-substance-misuse-response-program). In 2025 Georgia broadened its drug-checking law so that test strips for any substance, not just fentanyl, are no longer treated as drug paraphernalia (https://www.13wmaz.com/article/news/local/macon/new-ga-law-fight-against-overdoses-test-strips/93-16353d2a-1013-48ae-8de9-4e3b67f2bf96). A federal headwind arrived April 24 2026, when SAMHSA told grantees that federal funds may no longer be used to distribute fentanyl test strips to the public, which pressures state-funded distribution (https://klinic.com/blog/federal-funding-for-fentanyl-test-strips-just-ended).

Sentencing and expungement: Georgia uses "record restriction" rather than expungement. Under the Second Chance Act, many misdemeanor convictions can be restricted and sealed once four years have passed after sentence completion with no new convictions; restriction hides records from the public but not from courts and law enforcement (https://ccresourcecenter.org/state-restoration-profiles/georgia-restoration-of-rights-pardon-expungement-sealing/, https://www.adamcainlaw.com/blog/can-drug-charges-be-expunged-in-georgia/). There is no automatic cannabis-conviction expungement program. About 10,743 Georgians were arrested for marijuana possession in 2025 (https://www.georgiacriminaldefense.com/is-weed-legal-in-georgia-marijuana-laws-less-than-oz-cannabis.html).

Political landscape

Governor: Brian Kemp (Republican), term-limited, leaving office in January 2027 (https://www.aol.com/news/georgia-governor-kemp-opts-not-214332560.html). In his SB 220 signing statement, Kemp said he retains reservations about recreational cannabis but accepts that medical cannabis relieves symptoms that might otherwise be treated with opioids (https://www.cannabisbusinesstimes.com/home/document/15825033/georgia-gov-brian-kemp-signing-statement-on-medical-cannabis-expansion-bill).

Party control: Republican trifecta. After the 2024 elections the Senate is 33-23 Republican and the House is 100-80 Republican (https://ballotpedia.org/2026_Georgia_legislative_session, https://ballotpedia.org/Georgia_General_Assembly). There are 73 standing committees (29 Senate, 44 House).

Key committees for drug policy and the specific reform champions and named opponents on cannabis, hemp, and psychedelics could not be verified by name within this pass and are marked unconfirmed; NORML publicly advocated for SB 220 and generated nearly 500 constituent communications (https://norml.org/blog/2026/05/13/georgia-expands-patients-access-to-medical-cannabis-products/). At least one legislator submitted a letter to Gov. Kemp regarding SB 33 (the Georgia Recorder letter document references Rep. Scott Holcomb in its header, but his exact position on SB 33 should be confirmed at the source: https://georgiarecorder.com/wp-content/uploads/2026/05/Letter-to-Gov.-Kemp-re-SB-33-May-10-2026-final.pdf).

Ballot initiatives

Georgia does not allow citizen-initiated statewide ballot measures. It is one of the states with no power of initiative or referendum; only the legislature can refer constitutional amendments and statutes to the ballot (https://ballotpedia.org/States_without_initiative_or_referendum, https://ballotpedia.org/Laws_governing_ballot_measures_in_Georgia). As a result, there is no citizen pathway to a cannabis, psychedelic, or drug-policy ballot question, and none is pending. A few local charters (for example Augusta and Columbus) provide limited municipal initiative powers.

Equity and expungement

Georgia's medical cannabis statute and licensing rules contain no dedicated social-equity licensing program comparable to those in adult-use states; the limited Class 1 and Class 2 production licensing is capped and capital-intensive, which favors well-financed multistate operators over small or equity applicants. On record relief, Georgia offers petition-based "record restriction" rather than automatic expungement, and the Second Chance Act allows sealing of many misdemeanors after a four-year clean period (https://ccresourcecenter.org/state-restoration-profiles/georgia-restoration-of-rights-pardon-expungement-sealing/). There is no automatic cannabis-record clearance, so people with prior cannabis convictions must affirmatively petition and may remain excluded if convictions do not qualify.

Market and barriers

Production-license fees are high. Class 1 production: $25,000 application fee, $200,000 license fee, $100,000 annual renewal. Class 2 production: $5,000 application fee, $100,000 license fee, $50,000 annual renewal (https://www.gmcc.ga.gov/licensing/fee-schedule, https://www.gmcc.ga.gov/licensing/class-1-production, https://www.gmcc.ga.gov/licensing/class-2-production). License caps: 2 Class 1 and 4 Class 2 production licenses statewide; roughly 15 dispensing licenses issued, about 6 held by Trulieve (https://www.cannabisbusinesstimes.com/business-issues-benchmarks/medical-cannabis-access-and-pricing/news/15687742/trulieve-opens-georgias-first-medical-cannabis-dispensaries). Patient enrollment exceeds 33,000 (https://norml.org/blog/2026/05/13/georgia-expands-patients-access-to-medical-cannabis-products/). Specific cannabis excise tax rates and residency or capital-minimum requirements were not confirmed in this pass and may be stale; Georgia's program is a limited medical model rather than a taxed adult-use market. Hemp retailers face a $0 to low state fee structure under the Department of Agriculture but now face the SB 33 compliance costs and the federal November 12 2026 product restrictions.

Enclosure read

Georgia is heavily fenced. The medical cannabis side is a textbook capped oligopoly: only two Class 1 and four Class 2 production licenses, six-figure fees, and a dominant multistate operator (Trulieve) holding a large share of dispensing licenses. There is no home grow, no social-equity track, and no citizen ballot route to open the market, so the fence cannot be jumped from outside the legislature. The one genuinely decentralized, low-barrier corner has been the intoxicating-hemp retail sector, populated by small shops and independent brands; SB 33's January 1 2027 tightening plus the federal November 12 2026 hemp ban are positioned to fence that corner off as well, with no adult-use market to catch displaced operators. The likely beneficiaries are the licensed medical oligopoly and large compliant players; those fenced out are small hemp retailers, independent producers, would-be equity applicants, and patients who lose access to cheaper hemp-derived products. This justifies a 4/5: highly consolidated and closing, short of a full 5 only because the medical program is actively expanding patient access and harm-reduction tools remain relatively open.

What to watch next

July 1 2026: SB 220 medical cannabis expansion takes effect (12,000mg cap, vaping for 21+, new conditions); watch Department of Public Health rulemaking, with rules due by about January 1 2027. November 12 2026: federal hemp redefinition and 0.4mg-per-container cap take effect, threatening most Georgia intoxicating-hemp retail. January 1 2027: SB 33 (Act 461) hemp restrictions take effect. January 2027: Gov. Kemp leaves office (term-limited); the 2026 gubernatorial election decides his successor, which could reshape cannabis and hemp policy. The General Assembly next convenes for the new biennium on the second Monday of January 2027; watch for follow-up hemp, psychedelic, and any adult-use bills.

Regulators

Cannabis: Georgia Access to Medical Cannabis Commission (GMCC), licensing and oversight (https://www.gmcc.ga.gov/). Patient registry and product rules: Georgia Department of Public Health (https://dph.georgia.gov/). Hemp: Georgia Department of Agriculture, Hemp Program (https://agr.georgia.gov/hemp-program). Overdose, naloxone, and harm reduction: Department of Public Health, Opioid and Substance Misuse Response Program (https://dph.georgia.gov/stopopioidaddiction/opioid-and-substance-misuse-response-program). Criminal scheduling and enforcement run through the Official Code of Georgia Annotated and state courts.

Federal exposure (2026)

Georgia sits at the intersection of two opposite federal moves: a narrow medical rescheduling that rewards its licensees, and a hemp recriminalization that lands hardest on the one open corner of its market. The net effect deepens, rather than relieves, the state's enclosure.

Rescheduling and 280E. By federal default, cannabis remains Schedule I. The April 2026 DOJ/DEA final order moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I, and the broader DEA rescheduling hearing that opened June 29, 2026, may slip to 2027 (https://foleyhoag.com/news-and-insights/blogs/cannabis-and-the-law/2026/april/doj-immediately-reschedules-state-licensed-medical-cannabis-to-schedule-iii-and-restarts-the-clock/, https://www.foley.com/insights/publications/2026/04/dea-issues-long-awaited-final-order-rescheduling-certain-marijuana-products-to-schedule-iii-what-it-means-what-it-doesnt-and-what-comes-next/). Georgia is a medical-only state, so this order maps directly onto its market: state-licensed medical cannabis is exactly the category that moved to Schedule III, ending the Section 280E tax penalty for that category as of the order's effective date, with Treasury invited to consider retrospective relief (https://www.gibsondunn.com/dea-downschedules-state-medical-marijuana-to-schedule-iii-expedited-hearing-set-to-consider-broader-rescheduling/). The practical consequence is that the 280E relief flows to the small, tightly capped set of licensees who already hold the market, the two Class 1 and four Class 2 producers and the roughly 15 dispensing licensees led by Trulieve. There is no adult-use sector in Georgia to be left behind by the medical-only carve-out, but there is also no broad base of operators to share the benefit; the relief concentrates in the incumbents. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover recreational businesses, so nothing about the order opens Georgia's market or creates a new pathway in.

The November 12, 2026 hemp cliff. The most consequential federal lever for Georgia is the FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris R-MD), which narrowed the federal hemp definition to a total-THC standard of about 0.4 milligrams of THC per container, recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026 (https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf, https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains). The delay bill H.R. 7010 (sponsor unconfirmed, https://www.congress.gov/bill/119th-congress/house-bill/7010) was not enacted, and the 2026 Farm Bill (H.R. 7567, sponsor unconfirmed, https://www.congress.gov/bill/119th-congress/house-bill/7567) keeps the ban. The sequence matters in Georgia. The federal cliff lands first, on November 12, 2026; the state's own tightening under SB 33 (Act 461) does not take effect until January 1, 2027. So in practice Georgia's intoxicating hemp-derived THC retail, the delta-8, delta-9, delta-10, and THCA gummies, beverages, and tinctures sold to adults 21 and older, is exposed to federal elimination roughly seven weeks before the state rules even begin. SB 33 then arrives to govern a category federal law has already gutted, and because Georgia has no adult-use cannabis market to absorb displaced demand or operators, there is no in-state landing spot; the hemp shelf simply shrinks toward compliant low-THC items, and the customers who used hemp as a cheaper, more accessible substitute for the capped medical program lose that option.

Banking. SAFER Banking remains stalled in Congress, so Georgia's licensees, even with Schedule III medical relief on the income-tax side, continue to face the banking and access-to-capital frictions that come with cannabis. That cost structure compounds the state's six-figure license fees and further favors well-capitalized multistate operators over any small entrant.

Psychedelics. Georgia has no state psychedelic program; HB 717 and HB 382 did not become law. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but no psychedelic has been approved, and conditional rescheduling triggers only upon FDA approval. The only route to legal access in Georgia is therefore the federal FDA pathway; there is no state-level access to build on, and HB 717's design (access only once a therapy is FDA approved) tracks that federal-first posture.

Harm reduction. Georgia is comparatively open here: it authorized syringe services in 2019, distributes naloxone under a statewide standing order, and in 2025 legalized drug-checking test strips for any substance, not just fentanyl. The federal headwind is the SAMHSA guidance of April 24, 2026, which bars federal funds from being used for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone (https://klinic.com/blog/federal-funding-for-fentanyl-test-strips-just-ended). Georgia legalized those test strips at the state level, so they remain lawful to possess and distribute, but the federal cut squeezes the funding that supports state and grantee distribution of strips and syringe-program supplies; naloxone, which Georgia distributes through its standing order and supply boxes, keeps its federal support. The state's harm-reduction legality is intact; the money behind it is what the federal change pressures.

Patient access and rights

This section covers what Georgia law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Georgia has a limited medical cannabis program, not a comprehensive one. It runs on a state low-THC oil registry, and in 2026 Senate Bill 220 (effective July 1, 2026) expanded it: the law now refers to medical cannabis rather than low-THC oil, replaced the old five-percent THC cap with a possession limit measured in total THC, allowed vaping for registered patients 21 and older while still barring smoking, and broadened the list of qualifying conditions. Even after that expansion, the program comes with no patient protections attached.

Hospital access (Ryan's Law): Georgia has no hospital-access law. No statute requires a hospital or similar facility to let a patient use medical cannabis on site, so the decision is left to each facility's own policy. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), with Pennsylvania's bill pending; Georgia is not among them.

Broader protections: here the absence is the finding. A review of Georgia law found no statutory protection for a medical cannabis patient in any of the areas other states cover: not employment, not housing, not a custody or visitation dispute, not placement on an organ transplant list, and not school enrollment, and there is no general medical-care protection. A registered Georgia patient still has no enforceable shield in these situations; the protection does not exist in state law today.

Out-of-state patients: Georgia recognizes an out-of-state low-THC registration for possession only; it does not allow a visiting patient to purchase in Georgia.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine, and it creates no hospital-use right and no employment, housing, custody, transplant, or school protection; only state law can create those, and Georgia has not.

Sources: the Georgia low-THC oil law (O.C.G.A. Section 16-12-191) and Senate Bill 220 (2026).

Analysis: the enclosure read in depth

Who is fenced out and who consolidates. Georgia's medical market is a textbook capped oligopoly. The Georgia Access to Medical Cannabis Commission licenses only two Class 1 and four Class 2 production licenses statewide, with application and license fees in the tens to hundreds of thousands of dollars and six-figure annual renewals, and roughly 15 dispensing licenses, about six of them held by Trulieve. There is no home grow, no social-equity licensing track, and, critically, no citizen ballot initiative in Georgia, so the only way to widen the market is through a Republican-trifecta legislature that has so far chosen to expand patient access (SB 220) while keeping production locked to the same handful of incumbents. The people fenced out are small hemp retailers and independent brands, would-be equity applicants who cannot clear the capital bar, patients who relied on cheaper hemp-derived THC, and anyone hoping to enter cultivation or dispensing without multistate-operator backing. The people who consolidate are the existing licensees, above all Trulieve, who now gain both an expanded patient pool under SB 220 and federal 280E tax relief under the April 2026 Schedule III order.

The state-plus-federal interaction. The two layers reinforce each other in the same direction. At the state level, SB 220 grows demand (a 12,000 milligram possession allowance, vaping for 21 and older, new qualifying conditions, 33,000-plus patients and rising) without growing supply licenses, which raises the value of each capped license. At the federal level, Schedule III hands those same licensees a tax cut while doing nothing for outsiders, and the November 12, 2026 hemp cliff plus SB 33 remove the low-barrier hemp competitor that had been the one open lane. The result is a market that is simultaneously getting bigger for incumbents and narrower at the entrance. Federal action does not open Georgia; it transfers value to the players the state already chose.

What to watch. Whether Treasury grants retrospective 280E relief, which would further reward incumbents. Whether the broader DEA rescheduling hearing (opened June 29, 2026) produces anything that touches non-medical cannabis, which in a medical-only state would still require state legislative action to matter. The real-world sequence of the hemp cliff: how Georgia retailers and the Department of Agriculture handle a federal ban (November 12, 2026) that precedes the state's own SB 33 effective date (January 1, 2027), including any enforcement gap or guidance. The 2026 gubernatorial race and Gov. Kemp's departure in January 2027, since a new administration and the next biennium (convening January 2027) could revisit hemp, psychedelics, or adult use. And whether SAMHSA's funding cut measurably reduces test-strip and syringe-supply distribution even though both remain legal under Georgia law.

The absence of commons counter-moves. Most of the levers that elsewhere push back against enclosure are missing in Georgia. There is no citizen initiative to force open the market over the legislature's head; no social-equity or microbusiness licensing to seed small operators; no home-grow right to give individuals a non-market supply; no automatic cannabis-record expungement, only petition-based record restriction; and no adult-use market to absorb hemp operators displaced by the federal cliff. The one genuinely decentralized corner, intoxicating-hemp retail, is precisely what the federal November 12, 2026 standard and SB 33 close off. Harm reduction is the lone counter-current: all-substance test strips and syringe services remain legal at the state level, which is why the score is not a full 5.

Why 4 of 5. The state dynamics alone justify a high enclosure score: a hard production cap, six-figure fees, multistate-operator dominance, no equity track, no home grow, and no ballot route to change any of it. The 2026 federal layer pushes in the same direction, concentrating 280E relief in the incumbents while eliminating the hemp alternative, with banking still stalled and the only psychedelic route running through federal FDA approval. That combination, consolidating incumbents and closing the last open lane, reads as a 4. It stops short of 5 for two reasons that are real but limited: the medical program is actively expanding patient access rather than contracting it, and harm-reduction tools (test strips, syringe services, naloxone) remain legal under state law even as federal funding tightens. The trajectory, though, is toward closure, not opening.

Active legislation (2026)

Georgia runs a biennial General Assembly; the 2025-2026 regular session convened January 12 2026 and adjourned sine die on April 2 2026, after which a roughly 40-day signing window ran into mid-May. The list below is not exhaustive; for the long tail, use LegiScan (https://legiscan.com/GA), the Georgia General Assembly site (https://www.legis.ga.gov/).

Bill	Title/Topic	Chamber	Status	Sponsor(s)
SB 220	Putting Georgia's Patients First Act; medical cannabis expansion, 12,000mg cap, vaping 21+, new conditions	Senate	Signed by Gov. Kemp ~May 12 2026; effective July 1 2026	Sponsor unconfirmed (https://www.legis.ga.gov/legislation/70559)
SB 33	Georgia Hemp Farming Act; total THC limits, certificate of analysis, synthetic cannabinoid controls, penalties	Senate	Signed by Gov. Kemp May 11 2026 (Act 461); effective Jan 1 2027	Sponsor unconfirmed (https://legiscan.com/GA/bill/SB33/2025)
SB 254	Georgia Hemp Farming Act; milligram limits on delta-9-THC in consumable hemp	Senate	Did not pass; withdrawn/recommitted	Sponsor unconfirmed (https://legiscan.com/GA/bill/SB254/2025)
HB 265	Hemp; stricter total THC and intoxicating-cannabinoid limits	House	Did not pass	Sponsor unconfirmed (https://legiscan.com/GA/bill/HB265/2025)
HB 717	Psychedelic-assisted treatment by licensed clinicians once FDA approved	House	Did not pass	Sponsor unconfirmed (https://psychedelicalpha.com/news/march-2025s-psychedelic-policy-momentum-new-bills-filed-across-the-u-s-as-nearly-30-states-deliberate-reforms)
HB 382	Psilocybin scheduling exception for FDA-approved crystalline-polymorph psilocybin	House	Did not pass	Sponsor unconfirmed (https://legiscan.com/GA/bill/HB382/2025)

Sponsor and legislator names are listed as unconfirmed because they could not be verified against a primary source within this research pass; confirm via the linked LegiScan and General Assembly bill pages.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →